Table 1.

Treatment initiation and continuation regimens of Phase 3 randomized controlled trial of anti-VEGF in DME

Randomized controlled trial	Initiation and continuation regimen	Time to maximum mean BCVA*
RIDE/RISE NCT00473382 NCT00473330	Fixed q4 intervals ranibizumab  (no reduction before week 156 in the open-label extension) [4]	Week 88/week 92
RESTORE NCT00687804	Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [5, 6]	Week 40
RELIGHT NCT01257815	Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [7]	Week 24
REVEAL NCT00989989	Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [8]	Week 32
DRCR protocol I NCT00445003	Initial 4 q4 intervals ranibizumab followed by protocol-driven ranibizumab retreatment [9]	Week 232
DRCR.net protocol T NCT01627249	Aggressive retreatment protocol for IAI, bevacizumab, and ranibizumab prior to 24-week visit with q4 intervals [10]	Week 32, week 52
VIVID/VISTA NCT01363440 NCT01331681	Initial 5 q4 intervals IAI followed by 2q8 or 2q4 intervals [11]	Week 44
BOLT EUDRACT2007-000847-89	Initial 3 q6 intervals bevacizumab (initially combined with laser) followed by PRN (protocol-driven) bevacizumab retreatment [12]	Week 100

q4, every 4 weeks

* Within controlled/core study phase